Elevated levels of circulating IL-13 and increased expression of IL-13 receptor alpha 2 (IL-13Rα2) in the liver have been reported in individuals with MASH, with liver fibrosis mitigation observed upon targeting IL-13Rα2+ cells, including HSCs (130). Here, IL13RA2 is linked to Hepatic fibrosis.